Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $38.88M
• Dividend Yield: N/A
• Average Volume (3M): 496.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: 194.85%
• EPS Growth: 29.50%
• Country: US
• Employees: 140
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -1.62
• Shares Outstanding: 86,045,040
• 10 Day Avg. Volume: 601,943
• 30 Day Avg. Volume: 496,668
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 17.79
• Price to Cash Flow (P/CF): -0.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.40
• Price Target Upside: 1100.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Century Therapeutics faces significant financial challenges with ongoing losses and cash flow issues, reflected in a low financial score. Technical indicators suggest a bearish market trend. While the company's advances in cell therapies are promising, they do not outweigh the current financial and market technical weaknesses. The overall score remains low, highlighting the need for caution.

Positive Factors

Clinical Trials Expansion

Century is expanding its trial of CNTY-101 in autoimmune diseases and anticipates a positive impact from expanding the site footprint to Europe.

Strategic Focus

The decision to focus on autoimmune diseases for CNTY-101 is supported, as it reallocates resources to a potentially more promising area.

Therapeutic Potential

The therapeutic potential and dosing flexibility of Century Therapeutics' Allo-Evasion technology promises superior clinical outcomes with CNTY-101 in autoimmune diseases.

Negative Factors

Collaboration Termination

BMS' decision to discontinue their collaboration agreement with Century is disappointing and attributed to 'an internal corporate portfolio prioritization process.'

Pipeline Delays

Risks include delays in advancing candidates from the pipeline into clinical trials and potential failure to generate favorable clinical data.

Regulatory Risks

There is a risk of not securing regulatory approval for therapies, particularly CNTY-101, which could impact the company's future.

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Century Therapeutics primarily makes money through the development and commercialization of its cell therapy products. The company generates revenue from collaborations with pharmaceutical companies, where they may receive upfront payments, milestone payments, and royalties based on the successful development and commercialization of joint therapies. Additionally, Century Therapeutics invests in advancing its proprietary pipeline of cell therapy candidates, aiming to bring these products to market and derive revenue from sales. Strategic partnerships, licensing agreements, and potential government grants or funding initiatives may also contribute to its revenue streams.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics faces significant financial challenges with persistent losses and negative cash flows. Despite a decent equity buffer, the increasing leverage and inability to generate positive cash flow highlight risks in sustaining operations without external financing.

Income Statement

Century Therapeutics shows a consistent struggle with profitability, indicated by negative gross and net profit margins. The TTM data reveals a worsening EBIT and EBITDA margin, with revenue growth of 20.15%, yet it remains insufficient to cover high operational costs.

Balance Sheet

While Century Therapeutics maintains a relatively strong equity position, with a debt-to-equity ratio of 0.28, their declining equity ratio from 62.22% in 2022 to 50.34% TTM indicates rising leverage and potential financial strain.

Cash Flow

The company's cash flow situation is challenging, with negative operating and free cash flows, and a negative free cash flow growth rate. The operating cash flow to net income ratio remains below 1, indicating insufficient cash flow generation relative to losses.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.69M	2.23M	5.20M	0.00	0.00	0.00
	Gross Profit
-10.85M	-10.81M	-4.87M	-4.58M	-1.75M	-249.00K
	EBIT
-132.25M	-146.55M	-133.83M	-94.88M	-53.90M	-245.98M
	EBITDA
-117.21M	-121.21M	-119.34M	-89.92M	-51.44M	-19.78M
	Net Income Common Stockholders
-129.89M	-136.67M	-130.93M	-95.82M	-54.66M	-245.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
172.74M	172.74M	315.50M	222.88M	75.75M	81.54M
	Total Assets
360.69M	360.69M	486.54M	437.38M	106.78M	90.90M
	Total Debt
48.17M	48.17M	49.41M	23.46M	21.55M	0.00
	Net Debt
847.00K	847.00K	-34.85M	-32.98M	-5.66M	-44.06M
	Total Liabilities
175.94M	175.94M	183.81M	41.14M	213.19M	182.75M
	Stockholders Equity
184.75M	184.75M	302.74M	396.24M	-106.41M	-91.86M
Cash Flow		Free Cash Flow
-113.12M	-102.08M	-16.55M	-133.97M	-51.09M	-18.63M
	Operating Cash Flow
-112.14M	-88.35M	14.05M	-89.00M	-41.27M	-16.17M
	Investing Cash Flow
35.48M	61.13M	-13.13M	-298.34M	-22.76M	-19.83M
	Financing Cash Flow
74.81M	-9.72M	27.16M	417.77M	47.69M	74.84M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Negative. The current price of 0.45 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.68, and below the 200-day MA of 1.43, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 24.94 is Positive, neither overbought nor oversold. The STOCH value of 1.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
CRSP	46 Neutral	$2.92B	―	-19.20%	―	-89.95%	-123.71%
FATE	42 Neutral	$90.54M	―	-54.21%	―	-78.55%	-0.92%
NTLA	41 Neutral	$736.01M	―	-54.00%	―	59.55%	3.09%
IPSC	39 Underperform	$38.88M	―	-73.14%	―	194.85%	29.50%
EDIT	39 Underperform	$96.25M	―	-98.10%	―	-58.64%	-40.05%
BLUE	36 Underperform	$47.78M	―	-295.35%	―	184.12%	31.92%

Century Therapeutics Corporate Events

Century Therapeutics Re-prioritizes Pipeline for Key Programs

Century Therapeutics announced a strategic re-prioritization of its pipeline to focus on four transformative programs, particularly CNTY-308 and CNTY-101, aimed at B-cell mediated autoimmune diseases and malignancies. The company reported a strong cash position, extending its runway into the fourth quarter of 2026, and highlighted its decision to discontinue the ELiPSE-1 trial due to unmet transformational thresholds in late-stage R/R NHL, while emphasizing the potential of CNTY-101 in autoimmune diseases.

Century Therapeutics Unveils Advances in Cell Therapies

Century Therapeutics has released an updated corporate presentation detailing its progress in developing iPSC-derived cell therapies, including the lead product candidate CNTY-101, which targets B-cell malignancies and autoimmune diseases. The company highlights its advanced Allo-Evasion technology, which enhances immune evasion and allows repeat dosing without lymphodepletion, positioning Century as a leader in the field and potentially impacting its competitive standing in the biotechnology market.